jCyte

J Cyte

Biotechnology, 1000 Newport Center Dr Ste 231, Newport Beach, California, 92660, United States, 1-10 Employees

jcyte.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 94********

Who is JCYTE

jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company's allogeneic product candidate, jCell, is delivered by si...

Read More

map
  • 1000 Newport Center Dr Ste 231, Newport Beach, California, 92660, United States Headquarters: 1000 Newport Center Dr Ste 231, Newport Beach, California, 92660, United States
  • 2012 Date Founded: 2012
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8042 | NAICS Code: 621320 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from JCYTE

jCyte Org Chart and Mapping

Employees

Rob Beathard

Chief Strategy Officer

Terry Oneal

Chief Administrative Officer (Cao)

Adam Walsh

Chief Financial Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding JCyte

Answer: jCyte's headquarters are located at 1000 Newport Center Dr Ste 231, Newport Beach, California, 92660, United States

Answer: jCyte's phone number is 94********

Answer: jCyte's official website is https://jcyte.com

Answer: jCyte's revenue is $1 Million to $5 Million

Answer: jCyte's SIC: 8042

Answer: jCyte's NAICS: 621320

Answer: jCyte has 1-10 employees

Answer: jCyte is in Biotechnology

Answer: jCyte contact info: Phone number: 94******** Website: https://jcyte.com

Answer: jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company's allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access